
News|Videos|January 20, 2023
Selecting the Appropriate BTK Inhibitor for Frontline Treatment of CLL
Catherine Coombs, MD, reviews data on BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in the first-line treatment of CLL, and how she approaches selecting the appropriate BTK inhibitor in practice.
Advertisement
Episodes in this series

Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
More Global Expertise and Talent Are Needed to Administer Cell Therapies
2
Adaptive Treatment and Other Advances May Drive Radiotherapy Field Forward
3
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
4
Region-Based Genetic Disorders Affect Cancer Treatment Decisions
5